Vivoryon Therapeutics (VVY) Q1 2025 earnings summary

Executive summary

• Varoglutamstat demonstrated significant and sustained improvements in eGFR in phase II studies, especially in diabetic patients, with effects confirmed by meta-analysis and strong safety data.

• Expanded intellectual property with a new U.S. composition of matter patent, granting exclusivity through 2044 and possible extension to 2049, with additional filings for medical use, dosing, and combinations.

• Preclinical data showed synergy of varoglutamstat with standard of care therapies, de-risking future clinical programs.

• Preparations for a phase IIb study in diabetic kidney disease are underway, pending additional funding or partnership.

• Appointment of a new COO to strengthen corporate functions and investor relations.

Financial highlights

• No revenue reported for Q1 2025 or Q1 2024.

• R&D expenses fell to EUR 1.2 million in Q1 2025 from EUR 7.4 million in Q1 2024, mainly due to lower clinical and manufacturing costs.

• General and administrative expenses decreased to EUR 1.3 million from EUR 2.1 million year-over-year.

• Net loss narrowed to EUR 2.4 million in Q1 2025 from EUR 9.3 million in Q1 2024.

• Cash and cash equivalents stood at EUR 7 million as of March 31, 2025, with a cash runway into January 2026.

Outlook and guidance

• The company is preparing for a phase IIb study in diabetic kidney disease, with protocol design advanced and regulatory requirements considered.

• Cash runway is expected to fund operations into January 2026, excluding potential proceeds from new financings.

• Additional financing and partnership opportunities are being actively pursued to fund upcoming clinical trials.

• Ongoing operating losses are anticipated, with continued need for capital raises.

• Business viability beyond current guidance depends on successful fundraising and R&D progress.